Association of PKC Gamma Missense SNP with HCV Induced Hepatocellular Carcinoma

Abstract

The primary liver cancer also referred as Hepatocellular carcinoma (HCC), is a lethal disease accounts for approximately 90% of liver cancer worldwide. The major problem with HCC is early diagnosis. PKC gamma a member of conventional PKC involved in many cancers type but in context of single nucleotide polymorphism the protein was not much explored. The in-silico investigation of PKC gamma SNPs via edictSNP, 2021, CADD, DANN identify missense pathogenic mutation (K359R) rs1331234028. The AA variant of this genotype shows strong association with HCC. The odd ratio (OR) and relative risk (RR) for this variant was 5.194 and 2.287 respectively, having 0.0001 P-value. In-silico structural and functional analysis predict that upon this mutation the protein stability may decrease. For therapeutic purpose Maytansine was docked with PKC gamma which shows promising results and can be used as inhibitor of PKC gamma. The genetic variation in PKC gamma can be helpful in the early diagnosis of the hepatocellular carcinoma.